SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
5.24
+0.04 (0.77%)
At close: Aug 7, 2026, 4:00 PM EDT
5.34
+0.10 (1.91%)
After-hours: Aug 7, 2026, 4:50 PM EDT
SCYNEXIS Employees
SCYNEXIS had 18 employees as of December 31, 2025. The number of employees decreased by 10 or -35.71% compared to the previous year.
Employees
18
Change (1Y)
-10
Growth (1Y)
-35.71%
Revenue / Employee
$1,130,222
Profits / Employee
-$1,362,056
Market Cap
52.03M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 18 | -10 | -35.71% |
| Dec 31, 2024 | 28 | -1 | -3.45% |
| Dec 31, 2023 | 29 | -7 | -19.44% |
| Dec 31, 2022 | 36 | -20 | -35.71% |
| Dec 31, 2021 | 56 | 18 | 47.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| InterCure | 285 |
| Zhengye Biotechnology Holding | 269 |
| China Pharma Holdings | 215 |
| Rockwell Medical | 157 |
| Aytu BioPharma | 83 |
| BioXcel Therapeutics | 29 |
| Talphera | 12 |
| Incannex Healthcare | 12 |
SCYX News
- 5 weeks ago - Scynexis initiates SCY-770 study - TheFly
- 5 weeks ago - SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - GlobeNewsWire
- 6 weeks ago - SCYNEXIS Transcript: AGM 2026 - Transcripts
- 2 months ago - Scynexis trading halted, news pending - TheFly
- 2 months ago - Scynexis announces 1-for-8 reverse stock split - TheFly
- 2 months ago - SCYNEXIS Announces One-for-Eight Reverse Stock Split - GlobeNewsWire
- 2 months ago - SCYNEXIS Transcript: EGM 2026 - Transcripts
- 3 months ago - Scynexis reports Q1 EPS (42c), consensus (12c) - TheFly